Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Innovation/Tech Officer | March 09, 2024 | October 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 09, 2024 · Filed October 02, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 980,726 |
Reported balance
After 2024-03-09 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-09 · Tax withholding · Disposed 9,645 · Balance 980,726 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 . |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 .
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 14:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 50,000 | $6.00 | $300,000.00 |
DisclosureSEC source: 0001214659-24-004795 · marketforms-65280.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 984,476 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on December 6, 2023. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 13:45 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 5,895 | $4.88 | $28,767.60 |
DisclosureSEC source: 0001214659-24-004389 · marketforms-65141.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,034,476 F3 · kind: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2024 Filed Oct 2, 2024 14:16 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 9,645 | $4.88 | $47,067.60 |
DisclosureSEC source: 0001214659-24-017011 · marketforms-67099.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 980,726 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 . Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 13:45 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 25,000 | $5.19 | $129,685.00 |
DisclosureSEC source: 0001214659-24-004389 · marketforms-65141.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,040,371 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on December 16, 2023. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $5.00 to $5.60 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 10:36 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 41,250 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001214659-24-004307 · marketforms-64693.xml · derivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2034-03-07 F2 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 10:36 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 82,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004307 · marketforms-64693.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,065,371 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-010922 · marketforms-61881.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| May 05, 2023 Filed May 5, 2023 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-006558 · marketforms-61240.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 15:07 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-003692 · marketforms-59529.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,871 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 10:22 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001214659-22-013279 · marketforms-57373.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-11-04 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 17:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseWarrant (Right to Buy) · Derivative | 45,871 | $0.13 Strike: $0.96 | $5,963.23 |
DisclosureSEC source: 0001628280-22-016875 · wf-form4_165489638239475.xml · derivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,871 Underlying: Common Stock · 45,871 shares Expires 2027-06-08 F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 17:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 45,871 | $0.96 | $44,036.16 |
DisclosureSEC source: 0001628280-22-016875 · wf-form4_165489638239475.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,871 F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 11:25 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001214659-22-003898 · marketforms-55764.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 17:10 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-21-003148 · marketforms-51881.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| February 10, 2021 Filed Feb 10, 2021 20:17 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 23,460 | $6.75 | $158,355.00 |
DisclosureSEC source: 0001214659-21-001520 · marketforms-51450.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on December 16, 2020. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 20:17 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 11,540 | $6.75 | $77,895.00 |
DisclosureSEC source: 0001214659-21-001520 · marketforms-51450.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860,460 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on December 16, 2020. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 40,792 | $6.50 | $265,148.00 |
DisclosureSEC source: 0001214659-21-001480 · marketforms-51446.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on December 16, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-006105 · marketforms-49165.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 94 | $4.86 | $456.84 |
DisclosureSEC source: 0001214659-20-006105 · marketforms-49165.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,792 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-006105 · marketforms-49165.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 31, 2020 Filed Jun 2, 2020 17:14 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005339 · marketforms-48951.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| May 31, 2020 Filed Jun 2, 2020 17:14 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 4,132 | $4.87 | $20,122.84 |
DisclosureSEC source: 0001214659-20-005339 · marketforms-48951.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,553 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 31, 2020 Filed Jun 2, 2020 17:14 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005339 · marketforms-48951.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 08, 2020 Filed May 11, 2020 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 40,000 | $5.00 | $200,000.00 |
DisclosureSEC source: 0001214659-20-004314 · marketforms-48764.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,113 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4 on March 16, 2020. Read SEC document |
| April 29, 2020 Filed May 1, 2020 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 40,000 | $4.50 | $180,000.00 |
DisclosureSEC source: 0001214659-20-003962 · marketforms-48653.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022,113 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 Stock Trading Plan. Read SEC document |
| April 27, 2020 Filed May 4, 2020 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 40,000 | $4.00 | $160,000.00 |
DisclosureSEC source: 0001214659-20-004018 · marketforms-48670.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,113 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 Stock Trading Plan. Read SEC document |
| April 14, 2020 Filed May 4, 2020 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 40,000 | $3.70 | $148,000.00 |
DisclosureSEC source: 0001214659-20-004018 · marketforms-48670.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,113 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 Stock Trading Plan. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003145 · marketforms-48495.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 97 | $2.19 | $212.43 |
DisclosureSEC source: 0001214659-20-003145 · marketforms-48495.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,113 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003145 · marketforms-48495.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 16:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001214659-20-002752 · marketforms-48343.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 19:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002184 · marketforms-48058.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,572 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 19:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 5,066 | $3.73 | $18,896.18 |
DisclosureSEC source: 0001214659-20-002184 · marketforms-48058.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,881 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 19:38 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002184 · marketforms-48058.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,066,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000041 · marketforms-47054.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 329 | $5.82 | $1,914.78 |
DisclosureSEC source: 0001214659-20-000041 · marketforms-47054.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,165 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000041 · marketforms-47054.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2019 Filed Feb 26, 2020 16:20 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 147 | $5.82 | $855.54 |
DisclosureSEC source: 0001214659-20-001881 · marketforms-47924.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,375 F1 · shares: This amendment is being filed solely to amend the number of withheld shares due to a mistake in the number of shares withheld upon vesting of RSUs as reported in the original Form 4 filed on January 2, 2020. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:56 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-007535 · marketforms-46718.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,144 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:56 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 14,572 | $7.79 | $113,515.88 |
DisclosureSEC source: 0001214659-19-007535 · marketforms-46718.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,165 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| November 30, 2019 Filed Dec 2, 2019 16:56 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-007535 · marketforms-46718.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 30, 2019 Filed Feb 26, 2020 16:05 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,544 | $7.79 | $50,977.76 |
DisclosureSEC source: 0001214659-20-001859 · marketforms-47923.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,193 F1 · shares: This amendment is being filed solely to amend the number of withheld shares due to a mistake in the number of shares withheld upon vesting of RSUs as reported in the original Form 4 filed on December 2, 2019. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006188 · marketforms-45866.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 145 | $3.18 | $461.10 |
DisclosureSEC source: 0001214659-19-006188 · marketforms-45866.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,165 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-006188 · marketforms-45866.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2019 Filed Sep 3, 2019 18:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-005618 · marketforms-45658.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,716 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| August 31, 2019 Filed Sep 3, 2019 18:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,460 | $3.80 | $24,548.00 |
DisclosureSEC source: 0001214659-19-005618 · marketforms-45658.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,981 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| August 31, 2019 Filed Sep 3, 2019 18:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-005618 · marketforms-45658.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-004458 · marketforms-45276.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 149 | $4.20 | $625.80 |
DisclosureSEC source: 0001214659-19-004458 · marketforms-45276.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,869 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.